Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Nathan

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Brain Connectivity|September 16, 2014
Exploring variations in functional connectivity of the resting state default mode network in mild traumatic brain injuryDominic E Nathan, Terrence R Oakes, Ping Hong Yeh, et al.
NMR in Biomedicine|March 5, 2013
Perfusion deficits in patients with mild traumatic brain injury characterized by dynamic susceptibility contrast MRIWei Liu, Binquan Wang, Rachel Wolfowitz, et al.
Pharmacology, Biochemistry, and Behavior|March 20, 2002
Effects of frequent marijuana use on memory-related regional cerebral blood flowRobert I Block, Daniel S O'Leary, Richard D Hichwa, et al.
Neuroreport|April 11, 2000
Cerebellar hypoactivity in frequent marijuana usersR I Block, D S O'Leary, R D Hichwa, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
ESMO Open|November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialH Borghaei, K J O'Byrne, L Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Brain Connectivity|September 16, 2014
Exploring variations in functional connectivity of the resting state default mode network in mild traumatic brain injuryDominic E Nathan, Terrence R Oakes, Ping Hong Yeh, et al.
NMR in Biomedicine|March 5, 2013
Perfusion deficits in patients with mild traumatic brain injury characterized by dynamic susceptibility contrast MRIWei Liu, Binquan Wang, Rachel Wolfowitz, et al.
Pharmacology, Biochemistry, and Behavior|March 20, 2002
Effects of frequent marijuana use on memory-related regional cerebral blood flowRobert I Block, Daniel S O'Leary, Richard D Hichwa, et al.
Neuroreport|April 11, 2000
Cerebellar hypoactivity in frequent marijuana usersR I Block, D S O'Leary, R D Hichwa, et al.
ESMO Open|February 14, 2022
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patientsK J O'Byrne, K H Lee, S-W Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2019
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trialMartin Reck, Michael Schenker, Ki Hyeong Lee, et al.
ESMO Open|November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialH Borghaei, K J O'Byrne, L Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Pageof 16